Evaluation and Management of Elderly Patients With Lung Cancer

Seminars in Radiation Oncology

Volumn 22, Issue 4, 2012, Pages 304-310

  Gore, Elizabeth ^a   Movsas, Benjamin ^b   Santana Davila, Rafael ^a   Langer, Corey ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; CYTOCHROME P450; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO; SORAFENIB;

ADVANCED CANCER; AGED; ANEMIA; BLEEDING; BONE METASTASIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIARRHEA; DISEASE SPECIFIC SURVIVAL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG TOXICITY; GERIATRIC ASSESSMENT; HAZARD RATIO; HEALTH CARE QUALITY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NUTRITIONAL STATUS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL SUPPORT; STEREOTACTIC BODY RADIATION THERAPY; VIDEO ASSISTED THORACOSCOPIC SURGERY; WEDGE RESECTION; WEIGHT REDUCTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; COMORBIDITY; DECISION MAKING; GERIATRIC ASSESSMENT; HUMANS; LUNG NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; REFERRAL AND CONSULTATION; RISK FACTORS;

EID: 84866313075     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.05.007     Document Type: Review

References (71)

1. Hoffman G.B. Evaluating and treating unintentional weight loss in the elderly. Am Fam Physician 2002, 65:640-650.
2. Gill T.M., Allore H.G., Holford T.R., et al. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004, 292:2115-2124.
3. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000, 48:1475-1482.
4. Movsas B., Scott C., Sause W., et al. The benefit of treatment intensification is age and histology dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999, 45:1143-1149.
5. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003, 21:3201-3206.
6. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
7. Janssen-Heijnen M.L., Smulders S., Lemmens V.E., et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004, 59:602-607.
8. Chrischilles E.A., Pendergast J.F., Kahn K.L., et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:620-627.
9. Firat S., Pleister A., Byhardt R.W., et al. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006, 29:252-257.
10. Ramsey S.D., Howlader N., Etzioni R.D., et al. Chemotherapy use, outcomes and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004, 22:4971-4978.
11. Wan-Chow-Wah D., Monette J., Monette M., et al. Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians. Crit Rev Oncol Hematol 2011, 78:45-58.
12. Asmis T.R., Ding K., Seymour L., et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of the National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008, 26:54-59.
13. Birim O., Maat A.P., Kappetein A.P., et al. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003, 23:30-33.
14. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16:1582-1587.
15. Firat S., Bousamra M., Gore E.M., et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 52:1047-1057.
16. Firat S., Byhardt R.W., Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 2002, 54:357-364.
17. Colinet B., Jacot W., Bertrand D., et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: Description and comparison with the Charlson's index. Br J Cancer 2005, 93:1098-1105.
18. Steensma D.P., Tefferi A. Anemia in the elderly: How should we define it, when does it matter, and what can be done?. Mayo Clin Proc 2007, 82:958-966.
19. Langer C., Hsu C., Curran W., et al. Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy?. A secondary analysis of RTOG 9410. Int J Radiat Oncol Biol Phys 2001, 51(suppl 1):20-21.
20. Lee L., Cheung W.Y., Atkinson E., et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J Clin Oncol 2011, 29:106-117.
21. Kates M., Perez X., Gribetz J., et al. Validation of a model to predict perioperative mortality from lung cancer resection in the elderly. Am J Respir Crit Care Med 2009, 179:390-395.
22. Milroy R., Grose D., McAlpine L., et al. A pilot study of co-morbidity in newly diagnosed lung cancer patients. Lung Cancer 2005, 49:204.
23. Grose D., Devereux G., Milroy R. Comorbidity in lung cancer: Important but neglected. A review of the current literature. Clin Lung Cancer 2011, 12:207-211.
24. Extermann M., Boler I., Reich R.R., et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-age patients (CRASH) score. Cancer 2012, 118(13):3377-3386.
25. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007, 25:5570-5577.
26. Mery C.M., Pappas A.N., Bueno R., et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest 2005, 128:237-245.
27. Yamamoto K., Alarcon J.P., Medina V.C., et al. Surgical results of stage I non-small cell lung cancer: Comparison between elderly and younger patients. Eur J Cardiothorax Surg 2003, 23:21-25.
28. Sigel K., Bonomi M., Packer S., et al. Effect of age on survival of clinical stage I non-small-cell lung cancer. Ann Surg Oncol 2009, 16:1912-1917.
29. Rivera C., Falcoz P.E., Bernard A., et al. Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: A nested case-control study. Chest 2011, 140:874-880.
30. Cerfolio R.J., Bryant A.S., Jones V.A., et al. Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009, 35:718-723.
31. Sullivan V., Tran T., Holmstrom A., et al. Advanced age does note exclude lobectomy for non-small cell lung carcinoma. Chest 2005, 128:2671-2676.
32. Muraoka M., Oka T., Akamine S., et al. Surgical treatment for lung cancer in octogenarians. Surg Today 2005, 35:725-731.
33. Haasbeek C.J., Lagerwaard F.J., Antonisse M.E., et al. Stage I nonsmall cell lung cancer in patients ages > or = 75 years: Outcomes after stereotactic radiotherapy. Cancer 2010, 116:406-414.
34. Raz D.J., Zell J.A., Ingatius S.H., et al. Natural history of stage I non-small cell lung cancer: Implications for early detection. Chest 2007, 132:193-199.
35. Louie A.V., Rodrigues G., Hannouf M., et al. Withholding stereotactic radiation therapy in elderly patients with stage I non-small cell lung cancer and coexisting COPD is not justified: Outcomes of a Markov model analysis. Radiother Oncol 2011, 99:161-165.
36. A randomized phase III study of sublobar resedtion(+/-brachytherapy) versus stereotactic body radiation therapy in high risk patients with stage I non-small cell lung cancer (NSCLC) ACOSOG Z4099/RTOG 1021, Accessed May 2, 2011. http://www.acosog.org.
37. Parashar B., Patel P., Singh P., et al. Management of single malignant lung nodules in elderly patients (70 years or older) who are not candidates for lobectomy. Am J Clin Oncol 2011 May 6, [Epub ahead of print].
38. Palma D., Visser O., Lagerwaard F.J., et al. Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 2011, 101:240-244.
39. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
40. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007, 25:1553-1561.
41. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000, (2). Non-small Cell Lung Cancer Collaborative Group, CD002139.
42. Früh M., Rolland E., Pignon J.P., et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008, 26:3573-3581.
43. Kharofa J., Cohen E.P., TOmic R., et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012 Jan 31, [Epub ahead of print].
44. Pignon T., Gregor A., Schaake Koning C., et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998, 46:239-248.
45. Nguyen L.N., Komaki R., Allen P., et al. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: A retrospective review. Int J Radiat Oncol Biol Phys 1999, 44:1053-1056.
46. Gore E., Bae K., Langer C., et al. Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients with locally advanced non-small cell lung cancer [LA-NSCLC]: Radiation Therapy Oncology Group (RTOG) 0213. Clin Lung Cancer 2011, 12:125-130.
47. Gore E.M., Gasparri M., Devisetty K., et al. Pulmonary resection after high dose radiation therapy (>59 Gy) and concurrent chemotherapy for non-small cell lung cancer. J Thorac Oncol 2011, 6(suppl 2):1558.
48. Albain K.S., Swann R.S., Rusch V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 2009, 374:379-386.
49. Fairchild A., Barnes E., Ghosh S., et al. International patterns of practice in palliative radiotherapy for painful bone metastases: Evidence-based practice?. Int J Radiat Oncol Biol Phys 2009, 75:1501-1510.
50. Sundstrøm S., Bremnes R., Aasebø U., et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial. J Clin Oncol 2004, 22:801-810.
51. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999, 91:66-72. TELCVISG.
52. Kudoh S., Takeda K., Nakagawa K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006, 24:3657-3663.
53. Belani C.P., Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005, 104:2766-2774.
54. Ansari R.H., Socinski M.A., Edelman M.J., et al. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol 2011, 78:162-171.
55. Lilenbaum R.C., Herndon J.E., List M.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23:190-196.
56. Blanchard E.M., Moon J., Hesketh P.J., et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol 2011, 6:115-120.
57. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18:2529-2536.
58. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
59. Quoix E., Zalcman G., Oster J.P., et al. Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
60. Hesketh P.J., Lilenbaum F.C., Chansky K., et al. Chemotherapy in patients > 80 with advanced non-small cell lung cancer: Combined results from SOWG 0027 and LUN 6. J Thorac Oncol 2007, 2:494-498.
61. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-65.
62. Wakelee H.A., Dahlberg S.E., Brahmer J.R. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperate Oncology Group (ECOG) E4599. J Thorac Oncol 2008, 3(suppl 4):S282. Abstract 131.
63. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabin with either placebo or bevacizumab as first-lin therapy for non-squamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
64. Leighl N.B., Zatloukal P., Mezger J., et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsqamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010, 5:1970-1976.
65. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:760-766.
66. Wheatley-Price P., Ding K., Seymour L., et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:2350-2357.
67. Crinò L., Cappuzzo R., Zatloukal P., et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 2008, 26:4253-4260.
68. Sasaki T., Jänne P.A. New strategies for treatment of ALK rearranged non-small cell lung cancers. Clin Cancer Res 2011, 17:7213-7218.
69. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
70. Gridelli C., Morabito A., Gebbia V., et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer 2010, 67:86-92.
71. Gridelli C., Morgillo F., Favaretto A., et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study. Ann Oncol 2011, 22:1528-1534.